Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection
about
Bone Marrow Gene Therapy for HIV/AIDSRecent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal AntibodiesSurvivors Remorse: antibody-mediated protection against HIV-1.Engineering antibody-like inhibitors to prevent and treat HIV-1 infection.Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.Progress toward active or passive HIV-1 vaccination.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodiesEngineering broadly neutralizing antibodies for HIV prevention and therapy.Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults.Use of broadly neutralizing antibodies for HIV-1 prevention.Passive Immunization of Farmed Fish.Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.Use of a gamma-2 herpesvirus as a vector to deliver antibodies to rhesus monkeys.Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140.A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products.VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice.A single gp120 residue can affect HIV-1 tropism in macaques.Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding.Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.Passive immunotherapy of viral infections: 'super-antibodies' enter the fray.Immunogenicity of NYVAC prime-protein boost HIV-1 envelope vaccination and SHIV challenge of nonhuman primates.A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection.Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials.
P2860
Q26801765-8E11281A-5E68-4F43-A3E5-32757B67EEC3Q28068946-AE3F4077-FEC1-4CDF-B8EC-22C7432C8686Q30238730-F8138EC0-A593-4191-907C-14064428066BQ30490945-99537634-25A5-4824-BD0A-6980A7360BDFQ33638320-2049800B-DCAB-4D4D-9EF2-3C79B56A08CAQ35914292-5BDB4EE2-1214-4443-AC91-6F7F3FADD0C7Q35974269-5820403B-D37C-4FC6-8A76-18D48BB2BE34Q36239578-822EE75A-FEF1-4828-ADBE-F440109EFACBQ36290038-B0484020-BA47-4771-AF80-2D365F351D97Q36481483-47993DB5-6164-407C-8927-E9C21CE71271Q36627503-FE97203A-2823-4B57-A66C-833E547BD3E3Q37450695-F4064505-26A2-4AF5-B79A-2C060E0795FEQ37549777-69D5653D-5717-42C9-849E-772C1D1D267FQ37621530-B2B66F0F-9708-4E72-B55B-022642F3992BQ38717198-30C00538-3EF7-45BB-9563-CA8B6D6B39CEQ38736222-9179AC68-AA0E-406B-A5C2-56D6C1377288Q38764543-80471A18-5197-4F94-88BA-EE1A9655C9EEQ39323418-C39197D1-C68F-4431-BD24-ADA53138A363Q39371494-FFD1EE02-B1DB-42D7-9DA1-FFD08E488A09Q40141489-9D469183-9830-4E40-BD87-E208F6A630D0Q40503064-FD23DB06-43B1-428F-ACC6-F10A1D8A2F75Q40548641-A6A23758-2004-44AA-9514-92AF9BF9BE92Q40637173-78D380BE-3638-4400-BCF1-B502663DADD6Q41930708-69923701-587C-4CB5-ACEE-1CE0DDF955E4Q41933491-CAE3F4DA-C78C-4925-893B-25EEA9D6C13DQ44536209-A660EB01-7F8A-434A-81CC-F63CE4FE76EFQ46631754-BB34C99A-D795-4314-9488-0C281A93896AQ47110966-E765A4D3-AFBA-48B1-AF80-43475933B001Q47548101-25A3BE6E-B337-4405-95C7-73EB61F1071AQ50043326-16EF6340-9234-4A18-909C-3B5F7DF9733EQ52584556-3933CCDD-1B8B-4296-9968-FB225CF368CAQ52673965-5BDC9208-A253-4854-BA82-4B8D39735F73Q54230395-0D1AE18A-3893-4D30-BE37-D951C72F261C
P2860
Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Sustained Delivery of a Broadl ...... munodeficiency Virus Infection
@ast
Sustained Delivery of a Broadl ...... munodeficiency Virus Infection
@en
type
label
Sustained Delivery of a Broadl ...... munodeficiency Virus Infection
@ast
Sustained Delivery of a Broadl ...... munodeficiency Virus Infection
@en
prefLabel
Sustained Delivery of a Broadl ...... munodeficiency Virus Infection
@ast
Sustained Delivery of a Broadl ...... munodeficiency Virus Infection
@en
P2093
P2860
P50
P356
P1433
P1476
Sustained Delivery of a Broadl ...... munodeficiency Virus Infection
@en
P2093
Ashley T Haase
Ivelin S Georgiev
John-Paul Todd
Kevin O Saunders
M Gordon Joyce
Peter D Kwong
Srinivas S Rao
Stephen D Schmidt
P2860
P304
P356
10.1128/JVI.00210-15
P407
P577
2015-03-18T00:00:00Z